Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit
Phòng Ngừa Bệnh Do Vi Khuẩn Và Virus Lây Lan Qua Đường Hô Hấp Và Vai Trò Không Thể Thiếu Của Vắc-xin

Phòng Ngừa Bệnh Do Vi Khuẩn Và Virus Lây Lan Qua Đường Hô Hấp Và Vai Trò Không Thể Thiếu Của Vắc-xin

Rare diseases : Dried Blood Spot (DBS)

Rare diseases : Dried Blood Spot (DBS)

DBS is a form of biosampling in which blood samples collected from a finger-prick lancet are blotted and dried on filter paper.1

These samples are then sent to analytical laboratories to be analysed using a variety of methods such as enzyme assays and polymerase chain reaction (PCR).2,3

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results<sup>1</sup>

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results<sup>1</sup>

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results<sup>1</sup>

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results<sup>1</sup>

LIBERTY studieprogram på atopisk eksem

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

DERM 360° Roundtable: Patient Reported Outcome Measures (PROMs) in Clinical Practice

DERM 360° Roundtable: Patient Reported Outcome Measures (PROMs) in Clinical Practice

3rd of December 2024

DERM 360° Roundtable: Patient Reported Outcome Measures (PROMs) in Clinical Practice

DERM 360° Roundtable: Patient Reported Outcome Measures (PROMs) in Clinical Practice

3rd of December 2024

Global Developments in Early Detection<br />of Autoimmune Type 1 Diabetes

Global Developments in Early Detection of Autoimmune Type 1 Diabetes

Curious about the characteristics of pre-symptomatic- and stage 3 Type 1 Diabetes? Interested in learning about the potential benefits of screening for autoimmune Type 1 Diabetes?

This short film gives you an overview of recent developments in diagnosis of Type 1 Diabetes, showcasing how early detection efforts can benefit those who need it the most.

Global Developments in Early Detection<br />of Autoimmune Type 1 Diabetes

Global Developments in Early Detection of Autoimmune Type 1 Diabetes

Curious about the characteristics of pre-symptomatic- and stage 3 Type 1 Diabetes? Interested in learning about the potential benefits of screening for autoimmune Type 1 Diabetes?

This short film gives you an overview of recent developments in diagnosis of Type 1 Diabetes, showcasing how early detection efforts can benefit those who need it the most.

Global Developments in Early Detection<br />of Autoimmune Type 1 Diabetes

Global Developments in Early Detection of Autoimmune Type 1 Diabetes

Curious about the characteristics of pre-symptomatic- and stage 3 Type 1 Diabetes? Interested in learning about the potential benefits of screening for autoimmune Type 1 Diabetes?

This short film gives you an overview of recent developments in diagnosis of Type 1 Diabetes, showcasing how early detection efforts can benefit those who need it the most.

Global Developments in Early Detection<br />of Autoimmune Type 1 Diabetes

Global Developments in Early Detection of Autoimmune Type 1 Diabetes

Curious about the characteristics of pre-symptomatic- and stage 3 Type 1 Diabetes? Interested in learning about the potential benefits of screening for autoimmune Type 1 Diabetes?

This short film gives you an overview of recent developments in diagnosis of Type 1 Diabetes, showcasing how early detection efforts can benefit those who need it the most.